News

Public · Published

AbbVie 3Q International HUMIRA Rev $311M >ABBV

AbbVie reported third-quarter international revenue of $311 million for HUMIRA, according to the supplied headline. The figure covers sales outside the United States for that medicine during the quarter.

Published:

Updated:

What happened

AbbVie reported third-quarter international revenue of $311 million for HUMIRA, according to the supplied headline. The figure covers sales outside the United States for that medicine during the quarter.

Confirmed

Global impact / market context

HUMIRA is a major AbbVie product, so international sales of $311 million feed directly into the company's total revenue and cash available. Investors watch this line because falling sales abroad can lower profit and reduce money for research and dividends.

Analyst inference

The update is a single revenue figure, not full results. Investors may compare it with prior quarters to judge whether HUMIRA sales outside the United States are shrinking, which matters for AbbVie's revenue outlook and for how the stock is positioned.

Analyst inference

What to watch

  1. Watch AbbVie's full third-quarter report for total HUMIRA revenue, including United States sales, to see how the international $311 million fits into overall results. Confirmed
  2. Watch whether AbbVie management gives guidance on expected future international HUMIRA sales, since that would show how much revenue the company expects from abroad. Proposed
  3. Watch whether competition reduces international HUMIRA sales in coming quarters, because lower sales would cut AbbVie's revenue and the cash it has available. Analyst inference

Evidence

  • Original source link unavailable